Imigran (Sumatriptan)

Sumatriptan acts as an agonist at 5‑HT1B and 5‑HT1D receptors. Stimulation of 5‑HT1B causes constriction of dilated cranial blood vessels, while activation of 5‑HT1D inhibits release of neuropeptides from trigeminal nerve endings, interrupting the pain pathway that drives migraine.

The prescribed dose of Imigran is determined by the treating physician. The nasal spray delivers 5 mg of sumatriptan per spray, and the prescriber decides the number of sprays and timing based on the individual’s migraine pattern and response.

Safety of sumatriptan in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran (sumatriptan nasal spray) belongs to the triptan class, which provides rapid, targeted relief by acting on serotonin receptors. Compared with oral triptans, the nasal route can offer faster absorption and may be preferable for patients with nausea or delayed gastric emptying.

Imigran should be stored at ambient temperature below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Imigran is administered intranasally. The patient gently inserts the nozzle into one nostril, sprays the prescribed number of sprays, and then repeats in the other nostril if instructed. No water or food is required before or after administration.

Serious risks include coronary vasospasm leading to chest pain, severe hypertension, and rare allergic reactions such as anaphylaxis. Patients with known cardiovascular disease should avoid use, and any signs of chest discomfort or severe reactions require immediate medical attention.

Imigran is contraindicated in patients with uncontrolled hypertension, a history of myocardial infarction or other significant cardiovascular disease, known hypersensitivity to sumatriptan or any component of the formulation, and in individuals currently taking ergot alkaloids.